<?xml version="1.0" encoding="UTF-8"?>
<p class="p">Several pharmacological activators of brown fat and browning have been reported. These include β3-adrenergic receptor agonist (
 <xref rid="B31" ref-type="bibr" class="xref">Cypess et al., 2015</xref>), PPAR-γ activators (
 <xref rid="B177" ref-type="bibr" class="xref">Xie et al., 2017</xref>; 
 <xref rid="B96" ref-type="bibr" class="xref">Loh et al., 2018</xref>; 
 <xref rid="B107" ref-type="bibr" class="xref">Merlin et al., 2018</xref>), PGC-1α stabilizers (
 <xref rid="B127" ref-type="bibr" class="xref">Pettersson-Klein et al., 2018</xref>), PPAR-α agonist (
 <xref rid="B129" ref-type="bibr" class="xref">Rachid et al., 2018</xref>), AMPK activators (
 <xref rid="B75" ref-type="bibr" class="xref">Kim et al., 2016</xref>, 
 <xref rid="B76" ref-type="bibr" class="xref">2018</xref>; 
 <xref rid="B158" ref-type="bibr" class="xref">Tokubuchi et al., 2017</xref>) and PDE5 inhibitors Sildenafil and Tadalafil (
 <xref rid="B102" ref-type="bibr" class="xref">Maneschi et al., 2016</xref>; 
 <xref rid="B90" ref-type="bibr" class="xref">Li S. et al., 2018</xref>). Several other pharmacological modulators of BAT activity and browning have been reported. While some of them are expected from our understanding of brown fat biology, the other modulators identified could be used to gain further insights into the mechanisms of regulation of brown fat activation and browning.
</p>
